#45 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
South Dakota’s regulation of synthetic cannabinoids like delta-8 and THC-O through age restrictions provides clinicians with clearer legal frameworks for counseling patients about these products’ legal status and potential health risks. Since these compounds are often marketed as legal alternatives to cannabis with variable potency and purity, regulatory clarity helps clinicians advise patients on the lack of FDA oversight and unknown safety profiles. This legislation protects younger patients from accessing products that may carry greater health risks than traditional cannabis due to manufacturing inconsistencies and limited clinical data.
South Dakota’s Senate Bill 45 establishes regulatory controls on synthetic cannabinoids including delta-8 THC, THC-O acetate, and hexahydrocannabinol, with particular restrictions for minors. This legislation addresses a significant regulatory gap by classifying these compounds, which had previously existed in a legal gray area despite their psychoactive effects comparable to traditional delta-9 THC. The law reflects growing concern among state health officials about unregulated synthetic cannabinoid products marketed to youth, which lack standardized dosing, quality assurance, and safety testing. For clinicians, this means these products will face stricter oversight and reduced availability in South Dakota, reducing the likelihood that patients will encounter poorly regulated alternatives to pharmaceutical-grade cannabis products. The restriction on minor access aligns with evidence showing developmental risks of cannabinoid exposure in adolescence. Clinicians should be aware that this regulatory landscape varies significantly by state, making it important to understand local laws when counseling patients and families about cannabis and synthetic cannabinoid products.
“These synthetic cannabinoid regulations in South Dakota are clinically necessary because we’re seeing adolescents present with cannabinoid hyperemesis syndrome and acute psychiatric symptoms from delta-8 and THC-O products that are orders of magnitude more potent than plant cannabis, yet marketed with virtually no dosing guidance or safety data. Age-gating these compounds is the minimum standard of care we should expect from any state.”
💊 South Dakota’s regulatory action on synthetic cannabinoids reflects growing state-level efforts to address products that exploit legal gray areas, though clinicians should recognize that such legislation often lags behind product innovation and may not capture all psychoactive compounds patients encounter. The restriction of delta-8 THC, THC-O acetate, and hexahydrocannabinol in minors addresses legitimate public health concerns about potency and developmental effects, yet the regulatory landscape remains fragmented across states, creating confusion about what products are actually available to patients and families in different jurisdictions. Healthcare providers should be aware that synthetic cannabinoids may produce different pharmacodynamic effects than conventional cannabis, potentially carrying distinct risks that existing cannabis counseling frameworks may not adequately address. In clinical practice, this means taking a detailed substance use history that specifically probes for novel cannabinoid products by name, understanding that legal status does not equate to safety, and recognizing that
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: